Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 237.50
Bid: 229.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 9.50 (4.148%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 237.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PRTC to Present at Virtual Needham Conference

14 Apr 2020 07:00

RNS Number : 4591J
PureTech Health PLC
14 April 2020
 

14 April 2020

PureTech Health plc

 

PureTech to Present at 19th Annual Virtual Needham Healthcare Conference

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company") today announced that Daphne Zohar, founder and chief executive officer, will present at the 19th Annual Virtual Needham Healthcare Conference on Wednesday, 15 April, at 1:30 PM EDT. The conference is being held virtually, and a webcast of the presentation will be available on the Investors Relations section of the PureTech website at https://www.puretechhealth.com/reports-presentations.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

 

US media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

Tom Donovan

+1 857 559 3397

tom@tenbridgecommunications.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFFFELSLILLII
Date   Source Headline
23rd Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 201912:07 pmRNSSecond Price Monitoring Extn
23rd Sep 201912:02 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSVedanta Expands Series C with $62.1M Total Raised
16th Sep 20194:40 pmRNSSecond Price Monitoring Extn
16th Sep 20194:35 pmRNSPrice Monitoring Extension
9th Sep 201912:07 pmRNSSecond Price Monitoring Extn
9th Sep 201912:02 pmRNSPrice Monitoring Extension
9th Sep 20197:00 amRNSPureTech Announces Board Change
6th Sep 20194:41 pmRNSSecond Price Monitoring Extn
6th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 201912:07 pmRNSSecond Price Monitoring Extn
4th Sep 201912:02 pmRNSPrice Monitoring Extension
27th Aug 20197:00 amRNSPureTech Health plc Half-Year Report
20th Aug 20197:00 amRNSNotice of Results
19th Aug 201912:02 pmRNSPrice Monitoring Extension
14th Aug 20195:30 pmRNSBTG
7th Aug 20191:40 pmRNSVor Names Biotech Vet Robert Ang President & CEO
1st Aug 20197:00 amRNSTotal Voting Rights
31st Jul 20191:40 pmRNSVor Biopharma Adds R&D Leader Bill Lundberg to BOD
17th Jul 20197:00 amRNSPRTC Acquires Clinical Stage Asset for Lymphedema
11th Jul 20197:00 amRNSPotential US Listing of PureTech Health on Nasdaq
9th Jul 20197:00 amRNSPRTC Immuno-Oncology Programme Granted US Patent
3rd Jul 20197:00 amRNSPRTC's Karuna closes IPO, gross proceeds $102.6M
1st Jul 20197:00 amRNSFirst Patient in Vedanta Food Allergy Study
28th Jun 20197:00 amRNSPureTech's Karuna successfully lists on NASDAQ
20th Jun 20197:00 amRNSPureTech Announces New Corporate HQ/Internal Labs
13th Jun 20197:00 amRNSFollica Positive Interim Data & Plans for Pivotal
3rd Jun 20197:00 amRNSPRTC's Karuna Files Public S1 for NASDAQ IPO
30th May 20197:05 amRNSPRTC to Present at Jefferies US Conference
30th May 20197:00 amRNSResult of AGM
29th May 20197:00 amRNSVor Publishes POC Study in Scientific Journal
21st May 20197:00 amRNSVedanta Presents Expanded Data from Successful Ph1
20th May 20197:00 amRNSPromising Gelesis Data in Chronic Constipation
14th May 20197:00 amRNSGelesis & Vedanta Data at Digestive Disease Week
13th May 20197:00 amRNSVedanta Grows Series C Financing to $45.5 Million
7th May 20197:00 amRNSVedanta Prevails in Important EU Patent Opposition
26th Apr 20197:15 amRNSPRTC's Karuna Files IPO Registration Statement
25th Apr 20197:00 amRNSGelesis Gets $10.6M Grant to Support Manufacturing
24th Apr 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSBoehringer Ingelheim & PRTC Immuno-oncology Collab
15th Apr 20197:00 amRNSGelesis Receives FDA Clearance for First Product
11th Apr 20191:00 pmRNSAkili Makes CFO & General Counsel Appointments
11th Apr 20197:05 amRNSGelesis Presents Data on Effects of High-Fat Diet
11th Apr 20197:00 amRNSSonde Completes $16M Series A Financing Round
2nd Apr 20197:00 amRNSPRTC Presents Immuno-Oncology Programmes at AACR
1st Apr 201912:05 pmRNSKaruna expands Series B financing to $80 million
25th Mar 20196:00 pmRNSGelesis New Clinical Data on Impact of Gelesis100
25th Mar 20196:00 pmRNSGelesis Preclinical Data on Restoring Gut Barrier
21st Mar 20197:00 amRNSGelesis to Present at Endocrine Society Annual Mtg

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.